SBIR Phase I: Development of a Novel Platform for Cost-Efficient mRNA Production in Yeast — NSF Award to CISTERNA BIOLOGICS, INC.
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to develop a platform technology that manufactures high-quality messenger RNA (mRNA) at 1/10th the cost of current systems. In Vitro Transcription (IVT), the primary method of synthesizing mRNA for therapeutics and vaccines, encount
| Award title | SBIR Phase I: Development of a Novel Platform for Cost-Efficient mRNA Production in Yeast |
|---|---|
| Award ID | 2415711 |
| Awardee | CISTERNA BIOLOGICS, INC. |
| City | OCEANSIDE |
| State | CA |
| Amount obligated | $274,980 |
| Principal investigator | Hari Bhaskaran |
| Program | SBIR Phase I |
| Start date | 08/15/2024 |
| Abstract | The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to develop a platform technology that manufactures high-quality messenger RNA (mRNA) at 1/10th the cost of current systems. In Vitro Transcription (IVT), the primary method of synthesizing mRNA for therapeutics and vaccines, encounters significant challenges in the form of expensive patented raw materials, complex purification processes, and supply chain shortages. There is an urgent need to fundamentally red |
| Source | NSF Awards |
$799/mo
Try NSFGrants →